FANCE and hepatocellular carcinoma: Although three candidate targets ANKRD13B, LMNB2, and FANCE, which were regulated by miR-326, were all associated with HCC patient survival (Figure 3D), only LMNB2 has been investigated in a hepatocellular cancer study before (23).